Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia

Anesthesiology

Volumn 84, Issue 2, 1996, Pages 300-308

  Lien, Cynthia A ^a   Schmith, Virginia D ^b   Belmont, Matthew R ^a   Abalos, Amy ^a   Kisor, David F ^b   Savarese, John J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Neuromuscular relaxants: cisatracurium; Pharmacokinetics: cisatracurium

Indexed keywords

ATRACURIUM; BARBITURIC ACID DERIVATIVE; FENTANYL; LAUDANOSINE; MIDAZOLAM; MUSCLE RELAXANT AGENT; NITROUS OXIDE; OPIATE DERIVATIVE; THIOPENTAL;

ADULT; ANESTHESIA INDUCTION; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; FEMALE; GENERAL ANESTHESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOMER; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANESTHETICS, INHALATION; ANESTHETICS, INTRAVENOUS; ATRACURIUM; FEMALE; FENTANYL; HUMANS; ISOQUINOLINES; MALE; MIDAZOLAM; MIDDLE AGED; NEUROMUSCULAR NONDEPOLARIZING AGENTS; NITROUS OXIDE; OPIUM; STEREOISOMERISM; THIOPENTAL;

EID: 0030039281     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199602000-00007     Document Type: Article

References (25)

1. Lien CA, Belmont MR, Abalos A, Abou-Donia M, Savarese JJ: Dose-response relationships of 51W89 under nitrous oxide-opioid-barbiturate anesthesia (abstract). ANESTHESIOLOGY 1993; 79:A948
2. Lepage JY, Malinovsky JM, Malinge M, Cozian A, Pinaud M: 51W89: Dose-response neuromuscular blocking profile and cardiovascular effects (abstract). ANESTHESIOLOGY 1993; 79:A945
3. Belmont M, Lien C, Faagan M, Quessy S, Savarese J: Continuous infusion of 51W89 in patients under nitrous oxide-opioid-barbiturate anesthesia (abstract). Anesth Analg 1994; 78:S29
4. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ: The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ANESTHESIOLOGY 1995; 82:1139-45
5. Stenlake JB, Waigh RD, Urwin J, Dewar GH, Coker GG: Atracurium: Conception and inception. Br J Anaesth 1983; 55:3S-10S
6. Welch R, Brown A, Dahl R: In vitro degradation of cisatracurium in Sorensen buffer, rat, and humans plasma. Clin Pharmacol Ther 1995; 58:132-4
7. Taylor JK: Statistical Techniques for Data Analysis. Boca Raton, Lewis Publishers, 1990, pp 89-91
8. Nakashima E, Benet LZ: General treatment of mean residence time, clearance, and volume parameters in nonlinear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 1988; 16:475-92
9. Parker CJR, Hunter JM: Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. Br J Anaesth 1989; 62:177-83
10. Weatherly BC, Williams SG, Neill EAM: Pharmacokinetics, pharmacodynamics and dose-response relationships of atracurium administered I.V. Br J Anaesth 1983; 55:39S-45S
11. Ward S, Neill EAM, Weatherly BC, Corall IM: Pharmacokinetics of atracurium besylate in healthy patients (after a single I.V. bolus dose). Br J Anaesth 1983; 55:113-7
12. Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, Canfell CF, Castagnoli K, Hennis PJ: The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. ANESTHESIOLOGY 1984; 61:699-702
13. Lynam DP, Cronnelly R, Castagnoli KP, Canfell PC, Caldwell J, Arden J, Miller RD: The pharmacokinetics and pharmacodynamics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. ANESTHESIOLOGY 1988; 69:227-31
14. Lien CA, Matteo RS, Ornstein E, Schwartz AE, Diaz J: Distribution, elimination and action of vecuronium in the elderly. Anesth Analg 1991; 73:39-42
15. Matteo RS, Ornstein E, Schwartz AE, Ostapkovich N, Stone JG: Pharmacokinetics and pharmacodynamics of ORG 9426 in elderly surgical patients. Anesth Analg 1993; 77:1193-7
16. Szenohradsky J, Fisher DM, Segredo V, Caldwell JE, Bragg P, Sharma ML, Gruenke LD, Miller RD: Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ANESTHESIOLOGY 1992; 77:899-904
17. Merrett RA, Thompson CW, Webb FW: In vitro degradation of atracurium in human plasma. Br J Anaesth 1983; 55:61-6
18. Flynn PJ, Hughes R, Walton B: Use of atracurium in cardiac-surgery involving cardiopulmonary bypass with induced hypothermia. Br J Anaesth 1984; 56:967-72
19. Hughes R, Chapple DJ: The pharmacology of atracurium: A new competitive neuromuscular blocking agent. Br J Anaesth 1981; 53:31-44
20. Donati F, Varin F, Ducharme J, Gill SS, Theoret Y, Bevan DR: Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. Clin Pharmacol Ther 1991; 49:515-22
21. Schmith VD, Fiedler-Kelly J, Phillips L, Grasela T: Population pharmacokinetics/pharmacodynamics of a new neuromuscular blocking agent, 51W89 (abstract). Clin Pharmacol Ther 1995; 57: 213
22. Fisher DM, Canfell PC, Fahey MR, Rosen JI, Rupp SM, Sheiner LB, Miller RD: Elimination of atracurium in humans: Contributions of Hofmann elimination and ester hydrolysis versus organ-based elimination. ANESTHESIOLOGY 1986; 65:6-12
23. Shi WZ, Fahey MR, Fisher DM, Miller RD: Modification of central nervous system effects of laudanosine by inhalational anaesthetics. Br J Anaesth 1989; 63:598-600
24. Chapple DJ, Miller AA, Ward JB, Wheatley PL: Cardiovascular and neurological effects of laudanosine. Br J Anaesth 1987; 59:218-25
25. Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ, Vender J, Howard D, Casale EJ, Murray MJ: Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 1995; 81:3-12